Is pulsed the answer to treatment of Clostridium difficile infection?

Antibiotic treatment of Clostridium difficile infection has been plagued by high rates of recurrent diarrhoea attributed to C difficile and requiring retreatment, often repeatedly. In the latest edition of The Lancet Infectious Diseases, Benoit Guery and colleagues describe a novel dosing regimen for fidaxomicin in which the standard 200 mg, 20-dose, 10-day regimen is extended (the EXTEND study) by giving 200 mg twice daily for the first 5 days, followed by 200 mg every-other-day for an additional 20 days. The comparator regimen was standard-dose vancomycin (125 mg four times daily for 10 days), which is the same comparator dose that was used in two phase 3 licensing trials of standard-dose fidaxomicin (200 mg twice daily for 10 days). (The Lancet Infectious Diseases)


Further information can be found  at The Lancet Infectious Diseases 

Full reference: Gerding, D. N| (2017) | Is pulsed dosing the answer to treatment of Clostridium difficile infection?| The Lancet Infectious Diseases | Published online

The full article is available for Rotherham NHS staff to request here 

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.